Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-08), Becton Dickinson's 12-1 Month Momentum % is -27.66%.
The industry rank for Becton Dickinson's 12-1 Month Momentum % or its related term are showing as below:
XSWX:BDX's 12-1 Month Momentum % is ranked better than 80.29% of 827
companies
in the Medical Devices & Instruments industry
Industry Median: -15.79
vs XSWX:BDX: -27.66
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Becton Dickinson 12-1 Month Momentum % Related Terms
XSWX:BDX vs MDLN, RMD, WST: 12-1 Month Momentum % Comparison
For the Medical Instruments & Supplies subindustry, Becton Dickinson's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Becton Dickinson 12-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Becton Dickinson's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Becton Dickinson's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -27.66% mean?
Becton Dickinson (XSWX:BDX) has a 12-1 Month Momentum % of -27.66% as of Aug. 08, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Becton Dickinson and its competitors. According to the industry distribution chart, Becton Dickinson ranks #163 out of 827 companies in the Medical Devices & Instruments industry, placing it in the top 19.7%.
Is Becton Dickinson's 12-1 Month Momentum % too high?
Becton Dickinson's current 12-1 Month Momentum % is -27.66%. Based on the distribution chart, Becton Dickinson ranks #163 out of 827 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Becton Dickinson has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Becton Dickinson's 12-1 Month Momentum % compare to MDLN and RMD?
According to the Medical Devices & Instruments industry distribution chart, Becton Dickinson ranks #163 out of 827 companies for 12-1 Month Momentum %. This places Becton Dickinson in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Devices & Instruments company?
A good 12-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Becton Dickinson and its competitors. Becton Dickinson's current 12-1 Month Momentum % is -27.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Becton Dickinson stock overvalued right now?
Becton Dickinson (XSWX:BDX) has a current 12-1 Month Momentum % of -27.66%. The stock's GF Value™ is CHF151.68, compared to a current price of CHF142.54 — trading 6% below its estimated fair value. The current 12-1 Month Momentum % is -27.66%. Becton Dickinson's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Becton Dickinson (XSWX:BDX), the current 12-1 Month Momentum % is -27.66% as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Becton Dickinson (XSWX:BDX) Overvalued in 2026?
Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued.
The current stock price of CHF142.54 is trading 6% below its estimated GF Value™ of CHF151.68.
Key valuation signals for XSWX:BDX:
12-1 Month Momentum %: -27.66%
GF Value™: CHF151.68 vs. price of CHF142.54 (6% below fair value)
No single metric tells the full story. See the XSWX:BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
79GF Score
Get the complete analysis for XSWX:BDX
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BDX has been successfully added to your 
